Refine the approach
Untreated patient
THE KALLIKREIN-KININ PATHWAY IN HAE11
When C1-INH is deficient or dysfunctional, plasma kallikrein activity is increased.1
This leads directly to excessive bradykinin production and, ultimately, HAE attacks1
cHMWK=cleaved high molecular weight kininogen, FXII=factor XII; FXIIa=factor XIIa; HMWK=high molecular weight kininogen.
Patient treated with TAKHZYRO
The first and only mAb for HAE1-4
TAKHZYRO provides targeted inhibition of plasma kallikrein, a critical regulator of bradykinin production, to help prevent HAE attacks.1
Direct inhibition of plasma kallikrein controls excess bradykinin production.1
For patients aged 12 and older, just 1 subcutaneous injection, every 2 weeks1*
*The recommended starting dose for adults and adolescents is 300 mg every 2 weeks. TAKHZYRO every 4 weeks is also effective and may be considered if the patient is well-controlled (eg, attack free) for more than 6 months.1
Review Dosing Information
See efficacy and safety data across all 3 studies
Explore the results of the HELP study, the HELP open-label extension study, and the SPRING study.
Explore the Data